Drugs / LM11A-31
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07173803 | Jul 2026 → Sep 2030 expected | progressive supranuclear palsy | Adam Boxer | Recruiting | No outcome recorded |
| Phase 2 | NCT07264283 | Jun 2026 → Sep 2030 expected | progressive supranuclear palsy | Adam Boxer | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03069014 Comparator | Feb 2017 → Jun 2020 | — | PharmatrophiX Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | PharmatrophiX Inc. | Results Indiana University and PharmatrophiX Present Findings on Performance of Oral Therapeutic, LM11A-31, to Reduce Decline of Brain Functional-Network Connectivity in Alzheimer’s Disease pharmatrophix.com ↗
New findings presented at featured research session (FRS) during the Alzheimer’s Association International Conference demonstrate statistically significant slowing of decline in brain network function with LM11A-31 vs placebo linked to cognitive domains and synaptic resilience |
| 2025-12-02 | PharmatrophiX Inc. | Results p75 receptor modulation slows biomarkers and preserves visuospatial function pharmatrophix.com ↗
At 26 weeks, treatment with LM11A-31 was associated with a 31% decrease in plasma p-tau217 levels vs placebo (P=.049). |
| 2025-04-03 | PharmatrophiX Inc. | Results New drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients pharmatrophix.com ↗
A small clinical trial suggests that a new type of drug may be safe for people with Alzheimer’s disease and could potentially mitigate some of the brain damage caused by the condition. |
| 2024-05-17 | PharmatrophiX Inc. | Results p75 neurotrophin receptor modulation in mild to moderate Alzheimer’s disease pharmatrophix.com ↗
This trial met its primary endpoint of safety and tolerability. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | PharmatrophiX Inc. | Indiana University and PharmatrophiX Present Findings on Performance of Oral Therapeutic, LM11A-31, to Reduce Decline of Brain Functional-Network Connectivity in Alzheimer’s Disease pharmatrophix.com ↗ |
| 2025-12-02 | PharmatrophiX Inc. | p75 receptor modulation slows biomarkers and preserves visuospatial function pharmatrophix.com ↗ |
| 2025-04-03 | PharmatrophiX Inc. | New drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients pharmatrophix.com ↗ |
| 2024-05-17 | PharmatrophiX Inc. | p75 neurotrophin receptor modulation in mild to moderate Alzheimer’s disease pharmatrophix.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LM11A-31 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03069014 ↗ |
| Action | Inhibit | “treatment with p75NTR inhibitor LM11A-31” PMID 38029807 ↗ Nov 2023 |
| Modality | Small molecule | “first-in-class small molecule LM11A-31” PMID 38760589 ↗ May 2024 |
| Route | Oral | “administered twice daily by oral capsules.” PMID 38760589 ↗ May 2024 |